8-K: Traws Pharma Believes It Regained Compliance with Nasdaq Listing Rules After $20 Million Offering

Traws Pharma believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent offering, but confirmation from Nasdaq is still pending.

Summary

• Traws Pharma received a notification from Nasdaq on November 20, 2024, that it was not in compliance with the minimum $2.5 million stockholders' equity requirement for continued listing.
• The company requested a hearing and was granted an exception until February 18, 2025, to demonstrate compliance.
• On December 31, 2024, Traws Pharma closed an offering of Class A and Class B Units, raising approximately $20 million before fees and expenses.
• The offering included common stock, pre-funded warrants, and Series A warrants, with potential additional proceeds of up to $52.6 million upon exercise of the Series A warrants.
• As of February 18, 2025, Traws Pharma believes it has stockholders' equity of at least $2.5 million.
• The company is awaiting confirmation from Nasdaq that it has regained compliance, but there is no guarantee that Nasdaq will agree.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company has taken action to address a compliance issue, but there is still uncertainty regarding Nasdaq's final decision. The potential for additional funds from warrant exercises is a positive factor.

Positives

• Traws Pharma successfully raised approximately $20 million through an offering of Class A and Class B Units.
• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million as of February 18, 2025.
• The offering included Series A warrants that, if fully exercised, could bring in an additional $52.6 million.

Negatives

• Traws Pharma received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement.
• There is no guarantee that Nasdaq will determine that the company has regained compliance with the listing rules, even after the offering.

Risks

• Nasdaq may not confirm that Traws Pharma has regained compliance with the listing rules.
• The company's stock could be delisted from Nasdaq if it fails to maintain compliance.
• The Series A warrants may not be fully exercised, limiting the potential additional proceeds.

Future Outlook

The company is awaiting confirmation from Nasdaq that it has evidenced compliance with the Rule, but there can be no assurance that Nasdaq will determine that the Company has regained compliance with the Nasdaq continued listing rules.

Management Comments

• Werner Cautreels, Chief Executive Officer, signed the report on behalf of Traws Pharma, Inc.

Industry Context

Many small-cap pharmaceutical companies face challenges in maintaining Nasdaq listing compliance, especially those with significant R&D expenses and limited revenue. Raising capital through offerings is a common strategy to address these issues.

Comparison to Industry Standards

• Other small-cap biotech companies facing similar listing challenges, such as [Comparable Company A] and [Comparable Company B], have also undertaken capital raising activities to meet Nasdaq requirements.
• The $20 million offering is a typical size for companies in this situation, although the potential $52.6 million from warrant exercises could provide a significant boost if realized.
• The success of these efforts often depends on the company's ability to demonstrate progress in its clinical programs and achieve key milestones.

Stakeholder Impact

• Shareholders: The company's efforts to regain compliance with Nasdaq listing rules could positively impact shareholder value.
• Employees: Continued listing on Nasdaq could provide stability for employees.
• Creditors: Regaining compliance could improve the company's creditworthiness.

Next Steps

• Awaiting confirmation from Nasdaq that the company has regained compliance with the listing rules.
• Potential exercise of Series A warrants, which could bring in additional capital.

Key Dates